TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

Teva to Report Third Quarter 2016 Financial Results on November 15, 2016

JERUSALEM--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its third quarter 2016 financial results on Tuesday, November 15, 2016 at 7:00 a.m. ET.

Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2016 results and overall business environment. A Question & Answer session will follow this discussion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Canada 1-866-992-6802 or International +44(0) 2071 928000; passcode: 1843189. For a list of other international toll-free numbers, click here.

A live webcast of the call will also be available on Teva's website at: www.ir.tevapharm.com Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until December 15, 2016, 9:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 1452550000; passcode: 1843189.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.

EN
31/10/2016

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

5h / 41m 1 EN
Si Yong Ng
  • Si Yong Ng
Free Trial
TEVA.N Teva Pharmaceut...

Lucror Analytics - Convertibles Brief

In today's Convertibles Brief publication we comment on developments of the following high yield issuers: Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
01/29/26 January 29, 2026 1 EN
Haidje Rustau ... (+5)
  • Haidje Rustau
  • Jayanth Kandalam
  • Peter Low
  • Si Yong Ng
  • Tanvi Arora
Free Trial
TEVA.N Teva Pharmaceut...

Lucror Analytics - Morning Views Europe

In today's Morning Views publication we comment on developments of the following high yield issuers: Virgin Media O2, Italmatch Chemicals, Trivium, Air Baltic, Travelodge, Teva

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
01/29/26 January 29, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth ...

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 bill...

January 28, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease w...

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD programHD is a rare, progressive genetic disorder often described as a combination of ALS, Parkinson’s and Alzheimer’s, which manifests in motor, cognitive, and emotional symptoms1Teva’s Honestly HD program provides educational information about HD chorea, a symptom occurring in up to 90% of people with HD,2 to help those living with the condition and their care...

January 27, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch